14 Sep 2024 Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors Investors | Therapeutics
09 Sep 2024 Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress Investors | Therapeutics